A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-21

Study Completion Date

2018-09-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and tolerability of TAK-831 when administered as multiple oral doses at escalating dose levels in healthy participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828 Escalating Multiple-Doses in Healthy Participants

NCT02817516

Healthy Volunteers

TERMINATED PHASE1

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

NCT03228433

Healthy Participants

COMPLETED PHASE1

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137 in Healthy Participants

NCT02334982

Dose Finding Study

COMPLETED PHASE1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

NCT02413255

Healthy Volunteers

COMPLETED PHASE1

Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects

NCT03687684

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a randomized, investigator and participant blinded, sponsor unblinded, placebo-controlled, study of the safety, tolerability and pharmacokinetics of TAK-831 in up to 48 healthy volunteers, with 8 subjects in each of the 6 cohorts.

In each cohort, participants will be randomized in a 3:1 ratio to receive TAK-831 or placebo. Two formulations, oral suspension and tablet will be tested in this study. Both blood and cerebrospinal fluid (CSF) samples will be collected from selected cohorts (CSF cohorts); for the rest of the cohorts, only blood samples will be collected (non-CSF cohorts).

This single-center trial will be conducted in the United States. The overall time to participate in this study is 58 days. Participants will make multiple visits to the clinic, and 30 days after last dose of study drug for a follow-up assessment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo (Pooled)

TAK-831 placebo-matching suspension, orally, once daily (QD) for up to Day 16.

Group Type OTHER

Placebo

Intervention Type DRUG

TAK-831 placebo-matching suspension.

TAK-831 100 mg

TAK-831 100 mg, tablets, orally, QD on Days 1 and 3 to 16.

Group Type EXPERIMENTAL

TAK-831 Tablet T2

Intervention Type DRUG

Tak-831 tablets.

TAK-831 300 mg

TAK-831 300 mg, tablets, orally, QD on Days 1 and 3 to 16.

Group Type EXPERIMENTAL

TAK-831 Tablet T2

Intervention Type DRUG

Tak-831 tablets.

TAK-831 600 mg

TAK-831 600 mg, tablets, orally, QD on Days 1 and 3 to 16.

Group Type EXPERIMENTAL

TAK-831 Tablet T2

Intervention Type DRUG

Tak-831 tablets.

TAK-831 15 mg

TAK-831 15 mg, suspension, orally, multiple doses (MD) daily, on Days 1 and 3 to 16.

Group Type EXPERIMENTAL

TAK-831 Suspension

Intervention Type DRUG

TAK-831 Suspension.

TAK-831 800 mg

TAK-831 800 mg, suspension, orally, QD on Day 1, MD on Days 3 to 16.

Group Type EXPERIMENTAL

TAK-831 Suspension

Intervention Type DRUG

TAK-831 Suspension.

TAK-831 1200 mg

TAK-831 1200 mg, suspension, orally, QD on Day 1, MD on Days 3 to 16.

Group Type EXPERIMENTAL

TAK-831 Suspension

Intervention Type DRUG

TAK-831 Suspension.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TAK-831 Tablet T2

Tak-831 tablets.

Intervention Type DRUG

Placebo

TAK-831 placebo-matching suspension.

Intervention Type DRUG

TAK-831 Suspension

TAK-831 Suspension.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Has at least 45 kg weight and has a body mass index (BMI) from 18.0 to 30.0 kilogram per square meter (kg/m\^2), inclusive at Screening.
2. The participant is a healthy male or female not of childbearing potential adult who is aged 18 to 55 years, inclusive, at the time of informed consent and first study drug dose.
3. A male participant who is non-sterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 90 days plus half-lives (95 days) after last study drug dose.
4. A female participant with no childbearing potential, defined as a participant that has been surgically sterilized (hysterectomy, bilateral oophorectomy or tubal ligation) or who is postmenopausal (defined as continuous amenorrhea of at least 12 months and follicle stimulating hormone \[FSH\] greater than \[\>\] 40 international unit per liter \[IU/L\]).

Exclusion Criteria

1. Has a positive urine drug result for drugs of abuse (defined as any illicit drug use) at Screening or Check-in.
2. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse (defined as \>3 drinks per day) within 5 years before the Screening visit or is unwilling to agree to abstain from alcohol and drugs throughout the study. (1 drink=12 ounce \[oz\]. beer=5 oz. wine=1.5 oz. liquor.)
3. Has a QT interval with Fridericia's correction method (QTcF) \>450 milliseconds (ms) (male participants) or \>470 ms (female participants) or PR outside the range of 120 to 220 ms, confirmed with 1 repeat testing, at the Screening Visit or Check-in. When triplicate electrocardiogram (ECG) assessments are collected, the mean of the 3 QTcF and PR values should be used to assess this criterion.
4. Has a positive test result for hepatitis B surface antigen (HBsAg), anti- human chorionic gonadotropin (HCV), or human immunodeficiency virus (HIV) antibody/antigen at Screening.
5. Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days before Check-in. Cotinine test is positive at Screening or Check-in.
6. Has poor peripheral venous access.
7. Has donated or lost 450 milliliter (mL) or more of his or her blood volume (including plasmapheresis), or had a transfusion of any blood product within 45 days before the first dose of study medication.
8. Has a Screening or Check-in abnormal (clinically significant) ECG. Entry of any participant with an abnormal (not clinically significant) ECG must be approved and documented by signature by the principal investigator or designee.
9. Has a supine blood pressure outside 90 to 140 millimeter of mercury (mm Hg) for systolic and 50 to 90 mm Hg for diastolic, confirmed on repeat testing within a maximum of 30 minutes, at the Screening Visit or Check-in.
10. Has a resting heart rate outside 40 to 100 beats per minute confirmed on repeat testing within a maximum of 30 minutes, at the Screening Visit or Check-in (heart rate from the ECG does not apply).
11. Has a risk of suicide according to the Investigator's clinical judgment (example, per Columbia-Suicide Severity Rating Scale \[C-SSRS\]), or has scored "yes" on item 4 or item 5 of the Suicidal Ideation section of the C-SSRS, if this ideation occurred in the past 6 months, or "yes" on any item of the Suicidal Behavior section, except for the "Non-Suicidal Self-Injurious Behavior", if this behavior occurred in the past 2 years.

12. Has had CSF collection performed within 30 days before Check-in.
13. Has a history of clinically significant back pain and/or injury.
14. Has local infection at the puncture site.
15. Has thrombocytopenia or other suspected bleeding tendencies noted before procedure.
16. Has developed signs and symptoms of spinal radiculopathy, including lower extremity pain and paresthesia.
17. Has any focal neurological deficit that might suggest an increase in intracranial pressure.
18. Has any abnormal findings on ophthalmological assessment/fundoscopy suggestive of raised intracranial pressure (that is, optic disc swelling/edema; (uncontrolled) hypertensive retinopathy).
19. Suffers regularly from moderate to severe headaches requiring analgesics.
20. Has lower spinal malformations (on physical examination or lumbar spine radiography), local spinal infection, or other abnormalities that would exclude lumbar puncture (LP).

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes